Related Experiment Videos
Liposomal formulations of anticancer drugs: selectivity and effectiveness
Ulrich Massing1, Stefan Fuxius
1Department of Clinical Research, Tumor Biology Center at the University of Freiburg, Freiburg, Germany
Abstract:
After a delay of roughly 30 years, liposomes are becoming important as drug-targeting systems especially in anticancer therapy. Two liposomal anthracycline formulations are now available for cancer treatment and more are in preclinical tests or in clinical trials. This review summarizes the possibilities to improve the anticancer activity of certain drugs by entrapment in liposomes. We will briefly examine the problems and limitations of liposomal systems, from a pharmacokinetic as well as from a manufacturing viewpoint. Moreover, the anticancer properties of the two new liposomal anthracycline formulations will be discussed with regard to anticancer activity and side effects and compared with the properties of the respective free drugs. Copyright 2000 Harcourt Publishers Ltd.
Insights
Liposomes enhance anticancer drug efficacy, with two liposomal anthracyclines approved for cancer treatment. This review covers liposome applications, challenges, and compares new formulations to free drugs.
Area of Science:
- Oncology
- Pharmaceutics
- Drug Delivery Systems
Background:
- Liposomes are gaining prominence in cancer therapy after a 30-year development period.
- Two liposomal anthracycline formulations are currently available for cancer treatment, with others in development.
Purpose of the Study:
- To review methods for enhancing anticancer drug activity using liposome encapsulation.
- To examine pharmacokinetic and manufacturing challenges of liposomal systems.
- To discuss the anticancer properties, side effects, and efficacy of new liposomal anthracyclines compared to free drugs.
Main Methods:
- Literature review of liposomal drug delivery systems in oncology.
- Analysis of pharmacokinetic and manufacturing considerations for liposomes.
- Comparative assessment of liposomal anthracyclines versus free anthracyclines.
Main Results:
- Liposome encapsulation can improve the anticancer activity of certain drugs.
- Existing liposomal anthracycline formulations show promise in clinical settings.
- Manufacturing and pharmacokinetic factors present challenges for liposomal drug systems.
Conclusions:
- Liposomal drug delivery offers a viable strategy to improve anticancer therapy.
- Further research and development are needed to overcome liposomal system limitations.
- Liposomal anthracyclines represent a significant advancement in targeted cancer treatment.